Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06638060

Continuous Connected Patient Care (CCPC), a Pilot Testing a Novel Device for Continuous Vitals Monitoring - Older Adults Department PHC

To confirm feasibility and accessibility of the CCPC Platform (Oxymotion, Bridge Health Solutions medication adherence software, CloudDX home kit) in two different environments - 1) hospital (Acute Care for Elderly Unit) and 2) at-home .

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Aging

Age range

65 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

St. Paul'sHospital

Vancouver, British Columbia, V6Z 1Y6, Canada

Location status: Recruiting

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Inpatients on the Acute care of the Elderly ward.

Exclusion criteria

  • Lack of capacity to consent to the study including moderate-severe dementia or delirium
  • Unable to use (or does not have a caregiver who can help put on) study monitoring device at home
  • Unable to complete (or does not have a caregiver who can help complete) study questionnaires by electronic (mobile, tablet, or computer), paper, nor phone
  • Patient with known allergic reactions to any part material of the device
  • People under 40kg

Treatment and study plan

Primary outcomes

  1. Collect patient and clinicians' feedback about the CCPC Platform

    Time frame: From enrollment to the end of follow up at 10 days

    This will be completed via an assessment of the quantitative data on how long and how often patients use this monitoring and what were the reasons that patients took the monitors on and off.

  2. Collect patient and clinicians' feedback about the CCPC Platform

    Time frame: From enrollment to the end of follow up at 10 days

    This will be completed via an assessment of the Usability Questionnaire.

  3. Collect patient and clinicians' feedback about the CCPC Platform

    Time frame: From enrollment to the end of follow up at 10 days

    This will be completed by an evaluation for potential harm, e.g. anxiety questionnaire and any patient-reported adverse events.

  4. Confirm the technical goals of the CCPC platform are met.

    Time frame: From enrollment to the end of follow up at 10 days

    This will be completed by ensuring clinician workflow is met, via feedback sessions (e.g. conversations, questionnaires).

  5. Confirm the technical goals of the CCPC platform are met.

    Time frame: From enrollment to the end of follow up at 10 days

    This will be completed via an assessment of the data flow: does the correct patient data reach the clinicians at the right time?

  6. Confirm the technical goals of the CCPC platform are met.

    Time frame: From enrollment to the end of follow up at 10 days

    This will be completed by determining if the CCPC platform provided a holistic view of each patient with vitals, medication, labs and other collected data.

Interested in participating?

Recruiting

Interested in participating?

Request Info

Sponsors and collaborators

Lead sponsor

Medtronic - MITG

Industry

Collaborators

  • Bridge Health Solutions
  • Cloud DX Inc.
  • Excelar
  • Providence Healthcare

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Oct 15, 2024
Registry last updated
Mar 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.